| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 128 | 2025 | 282 | 22.540 |
Why?
|
| Cardiac Catheterization | 70 | 2025 | 540 | 14.240 |
Why?
|
| Pulmonary Valve | 22 | 2025 | 96 | 9.560 |
Why?
|
| Stents | 34 | 2025 | 531 | 8.010 |
Why?
|
| Heart Valve Prosthesis Implantation | 19 | 2025 | 185 | 7.820 |
Why?
|
| Heart Valve Prosthesis | 16 | 2025 | 118 | 6.440 |
Why?
|
| Septal Occluder Device | 18 | 2025 | 35 | 6.340 |
Why?
|
| Pulmonary Valve Insufficiency | 12 | 2025 | 42 | 5.430 |
Why?
|
| Heart Defects, Congenital | 36 | 2024 | 879 | 4.930 |
Why?
|
| Heart Septal Defects, Atrial | 12 | 2025 | 60 | 4.770 |
Why?
|
| Prosthesis Design | 30 | 2025 | 338 | 4.340 |
Why?
|
| Pulmonary Artery | 20 | 2025 | 1117 | 4.040 |
Why?
|
| Aortic Coarctation | 10 | 2022 | 80 | 3.740 |
Why?
|
| Treatment Outcome | 116 | 2025 | 11125 | 3.310 |
Why?
|
| Pulmonary Veins | 9 | 2025 | 106 | 2.990 |
Why?
|
| Cardiac Surgical Procedures | 19 | 2021 | 587 | 2.770 |
Why?
|
| Hypoplastic Left Heart Syndrome | 7 | 2025 | 117 | 2.680 |
Why?
|
| Translocation, Genetic | 12 | 2025 | 109 | 2.260 |
Why?
|
| Humans | 306 | 2025 | 140898 | 2.160 |
Why?
|
| Ventricular Outflow Obstruction | 5 | 2023 | 40 | 2.110 |
Why?
|
| Heart Atria | 5 | 2024 | 139 | 1.900 |
Why?
|
| Tetralogy of Fallot | 7 | 2022 | 73 | 1.810 |
Why?
|
| Chromothripsis | 4 | 2022 | 4 | 1.810 |
Why?
|
| Diphosphonates | 5 | 2013 | 69 | 1.750 |
Why?
|
| Vascular Fistula | 2 | 2024 | 21 | 1.720 |
Why?
|
| Pulmonary Valve Stenosis | 5 | 2025 | 20 | 1.690 |
Why?
|
| Hemodynamics | 25 | 2025 | 1100 | 1.690 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2023 | 1786 | 1.690 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 17 | 2025 | 670 | 1.690 |
Why?
|
| Immunoglobulin Light Chains | 8 | 2021 | 51 | 1.660 |
Why?
|
| Angioplasty, Balloon | 6 | 2020 | 93 | 1.640 |
Why?
|
| Heart Septal Defects, Ventricular | 5 | 2023 | 45 | 1.640 |
Why?
|
| Mitral Valve | 4 | 2025 | 98 | 1.620 |
Why?
|
| Retrospective Studies | 77 | 2025 | 16315 | 1.610 |
Why?
|
| Male | 158 | 2025 | 69893 | 1.560 |
Why?
|
| Ductus Arteriosus, Patent | 9 | 2025 | 53 | 1.540 |
Why?
|
| Biomarkers, Tumor | 15 | 2025 | 1243 | 1.540 |
Why?
|
| Infant | 60 | 2025 | 9790 | 1.510 |
Why?
|
| Angiography | 11 | 2021 | 207 | 1.500 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2024 | 79 | 1.500 |
Why?
|
| Ductus Arteriosus | 4 | 2017 | 73 | 1.470 |
Why?
|
| Chromosome Aberrations | 14 | 2025 | 160 | 1.430 |
Why?
|
| Bone Density Conservation Agents | 5 | 2013 | 83 | 1.430 |
Why?
|
| Clodronic Acid | 4 | 2012 | 18 | 1.410 |
Why?
|
| Cardiology | 5 | 2022 | 279 | 1.400 |
Why?
|
| Virtual Reality | 2 | 2024 | 74 | 1.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 1430 | 1.370 |
Why?
|
| Thalidomide | 8 | 2020 | 44 | 1.360 |
Why?
|
| Child | 76 | 2025 | 22313 | 1.340 |
Why?
|
| Stenosis, Pulmonary Vein | 4 | 2025 | 19 | 1.330 |
Why?
|
| Genomics | 11 | 2025 | 810 | 1.320 |
Why?
|
| Female | 147 | 2025 | 75540 | 1.320 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2025 | 67 | 1.310 |
Why?
|
| Genome, Human | 8 | 2025 | 421 | 1.300 |
Why?
|
| Child, Preschool | 50 | 2025 | 11462 | 1.290 |
Why?
|
| Imidazoles | 4 | 2012 | 254 | 1.270 |
Why?
|
| Heart Ventricles | 12 | 2024 | 749 | 1.240 |
Why?
|
| Adolescent | 67 | 2025 | 22027 | 1.180 |
Why?
|
| Echocardiography | 10 | 2023 | 648 | 1.160 |
Why?
|
| Prognosis | 36 | 2025 | 4060 | 1.160 |
Why?
|
| Predictive Value of Tests | 12 | 2025 | 2062 | 1.140 |
Why?
|
| Heart Valve Diseases | 3 | 2019 | 153 | 1.090 |
Why?
|
| Middle Aged | 82 | 2025 | 34487 | 1.090 |
Why?
|
| Plasma Cells | 5 | 2021 | 74 | 1.080 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2018 | 65 | 1.060 |
Why?
|
| Multimodal Imaging | 4 | 2024 | 119 | 1.060 |
Why?
|
| Prosthesis Failure | 5 | 2025 | 125 | 1.040 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2025 | 73 | 1.030 |
Why?
|
| Pulmonary Atresia | 3 | 2023 | 22 | 1.030 |
Why?
|
| Ventricular Function, Left | 4 | 2025 | 515 | 1.010 |
Why?
|
| Genome-Wide Association Study | 15 | 2024 | 1403 | 1.010 |
Why?
|
| Computed Tomography Angiography | 2 | 2025 | 134 | 1.000 |
Why?
|
| Follow-Up Studies | 29 | 2025 | 5194 | 1.000 |
Why?
|
| Gene Expression Profiling | 11 | 2025 | 1761 | 0.990 |
Why?
|
| Radiation Exposure | 3 | 2024 | 55 | 0.990 |
Why?
|
| Adult | 77 | 2025 | 39134 | 0.980 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 3 | 2021 | 8 | 0.980 |
Why?
|
| Hypertension, Pulmonary | 9 | 2023 | 1940 | 0.970 |
Why?
|
| Echocardiography, Transesophageal | 9 | 2025 | 128 | 0.970 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2025 | 39 | 0.970 |
Why?
|
| Aged | 73 | 2025 | 24666 | 0.960 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2017 | 222 | 0.950 |
Why?
|
| Gene Dosage | 4 | 2021 | 142 | 0.950 |
Why?
|
| Catheterization, Peripheral | 2 | 2023 | 108 | 0.930 |
Why?
|
| Norwood Procedures | 2 | 2025 | 28 | 0.920 |
Why?
|
| Echocardiography, Doppler | 3 | 2025 | 113 | 0.920 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2025 | 1067 | 0.910 |
Why?
|
| Thrombosis | 3 | 2025 | 398 | 0.910 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2024 | 344 | 0.900 |
Why?
|
| United Kingdom | 16 | 2022 | 319 | 0.900 |
Why?
|
| Multidetector Computed Tomography | 1 | 2025 | 40 | 0.890 |
Why?
|
| Young Adult | 38 | 2025 | 13646 | 0.870 |
Why?
|
| Amyloidosis | 2 | 2021 | 49 | 0.870 |
Why?
|
| Fistula | 1 | 2024 | 47 | 0.860 |
Why?
|
| Endovascular Procedures | 5 | 2020 | 356 | 0.860 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2024 | 2368 | 0.850 |
Why?
|
| Polymorphism, Single Nucleotide | 19 | 2024 | 2128 | 0.840 |
Why?
|
| Arteriovenous Malformations | 1 | 2024 | 29 | 0.830 |
Why?
|
| Infant, Newborn | 26 | 2025 | 6257 | 0.830 |
Why?
|
| Time Factors | 30 | 2025 | 6944 | 0.830 |
Why?
|
| Fluoroscopy | 8 | 2024 | 169 | 0.830 |
Why?
|
| Embolization, Therapeutic | 2 | 2024 | 242 | 0.830 |
Why?
|
| Postoperative Complications | 10 | 2025 | 2813 | 0.830 |
Why?
|
| Mutation | 16 | 2025 | 3999 | 0.830 |
Why?
|
| Mitral Valve Stenosis | 2 | 2016 | 19 | 0.810 |
Why?
|
| Risk Factors | 39 | 2025 | 10430 | 0.810 |
Why?
|
| Boron Compounds | 6 | 2025 | 30 | 0.810 |
Why?
|
| Heart-Assist Devices | 3 | 2025 | 561 | 0.800 |
Why?
|
| Antineoplastic Agents | 11 | 2025 | 2156 | 0.800 |
Why?
|
| Amyloid | 2 | 2021 | 97 | 0.790 |
Why?
|
| Pericardial Effusion | 1 | 2023 | 21 | 0.790 |
Why?
|
| Transplantation, Autologous | 17 | 2024 | 280 | 0.790 |
Why?
|
| Glycine | 6 | 2025 | 185 | 0.750 |
Why?
|
| Blood Pressure | 6 | 2021 | 1745 | 0.750 |
Why?
|
| Coronary Vessels | 4 | 2023 | 247 | 0.750 |
Why?
|
| Aorta, Thoracic | 3 | 2023 | 280 | 0.750 |
Why?
|
| Dexamethasone | 17 | 2023 | 379 | 0.720 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2013 | 37 | 0.710 |
Why?
|
| Survival Rate | 14 | 2021 | 1962 | 0.710 |
Why?
|
| Intrinsically Disordered Proteins | 1 | 2021 | 39 | 0.700 |
Why?
|
| Stem Cell Transplantation | 9 | 2023 | 187 | 0.700 |
Why?
|
| Clonal Evolution | 5 | 2020 | 45 | 0.690 |
Why?
|
| Telomere Homeostasis | 1 | 2021 | 33 | 0.690 |
Why?
|
| Arteriovenous Fistula | 2 | 2024 | 37 | 0.690 |
Why?
|
| Radiography, Interventional | 7 | 2019 | 122 | 0.680 |
Why?
|
| Bioprosthesis | 2 | 2020 | 39 | 0.680 |
Why?
|
| Melphalan | 8 | 2024 | 40 | 0.670 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2022 | 243 | 0.670 |
Why?
|
| Heart Diseases | 4 | 2023 | 334 | 0.670 |
Why?
|
| Bone Marrow | 3 | 2017 | 301 | 0.660 |
Why?
|
| Polytetrafluoroethylene | 2 | 2018 | 25 | 0.660 |
Why?
|
| Cyclin D1 | 3 | 2020 | 68 | 0.660 |
Why?
|
| Survival Analysis | 12 | 2021 | 1320 | 0.660 |
Why?
|
| Vascular Stiffness | 6 | 2021 | 449 | 0.650 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2022 | 375 | 0.650 |
Why?
|
| Aged, 80 and over | 25 | 2025 | 7899 | 0.640 |
Why?
|
| Aortic Diseases | 3 | 2022 | 119 | 0.640 |
Why?
|
| Transcription Factors | 6 | 2021 | 1703 | 0.630 |
Why?
|
| Abnormalities, Multiple | 2 | 2013 | 197 | 0.630 |
Why?
|
| Palliative Care | 7 | 2025 | 819 | 0.630 |
Why?
|
| Bortezomib | 9 | 2021 | 53 | 0.630 |
Why?
|
| Oncogenes | 3 | 2021 | 118 | 0.620 |
Why?
|
| Aortography | 3 | 2017 | 54 | 0.610 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2023 | 70 | 0.610 |
Why?
|
| Aorta | 9 | 2020 | 423 | 0.610 |
Why?
|
| Ventricular Function, Right | 6 | 2025 | 283 | 0.590 |
Why?
|
| Aneurysm, False | 1 | 2019 | 45 | 0.590 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 5 | 2021 | 11 | 0.590 |
Why?
|
| Emergencies | 2 | 2019 | 179 | 0.590 |
Why?
|
| Stenosis, Pulmonary Artery | 1 | 2018 | 4 | 0.590 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1478 | 0.580 |
Why?
|
| Antibodies, Monoclonal | 3 | 2021 | 1471 | 0.580 |
Why?
|
| Pulmonary Circulation | 6 | 2025 | 438 | 0.580 |
Why?
|
| Smoldering Multiple Myeloma | 4 | 2022 | 7 | 0.580 |
Why?
|
| Remission Induction | 10 | 2021 | 309 | 0.580 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 544 | 0.580 |
Why?
|
| Pediatrics | 4 | 2023 | 1097 | 0.570 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 326 | 0.570 |
Why?
|
| Chromium Alloys | 1 | 2018 | 5 | 0.570 |
Why?
|
| Hypertension | 2 | 2020 | 1251 | 0.560 |
Why?
|
| Fontan Procedure | 5 | 2020 | 182 | 0.560 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 15 | 0.550 |
Why?
|
| Probiotics | 2 | 2018 | 57 | 0.550 |
Why?
|
| Eczema | 2 | 2018 | 70 | 0.550 |
Why?
|
| Congresses as Topic | 1 | 2019 | 223 | 0.540 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2025 | 85 | 0.540 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 40 | 0.540 |
Why?
|
| Catheter Ablation | 2 | 2023 | 313 | 0.540 |
Why?
|
| Coronary Artery Disease | 1 | 2024 | 702 | 0.540 |
Why?
|
| Mutagenesis | 1 | 2018 | 182 | 0.530 |
Why?
|
| Foreign-Body Migration | 2 | 2017 | 32 | 0.530 |
Why?
|
| Factor VIIa | 1 | 2017 | 42 | 0.530 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 488 | 0.530 |
Why?
|
| Hemoptysis | 1 | 2017 | 37 | 0.530 |
Why?
|
| Immunologic Factors | 5 | 2023 | 249 | 0.520 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 248 | 0.520 |
Why?
|
| Whole Genome Sequencing | 7 | 2022 | 169 | 0.510 |
Why?
|
| Diploidy | 3 | 2017 | 16 | 0.510 |
Why?
|
| Equipment Design | 9 | 2019 | 525 | 0.510 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 93 | 0.510 |
Why?
|
| Coronary Angiography | 4 | 2024 | 316 | 0.500 |
Why?
|
| Cyclophosphamide | 9 | 2022 | 256 | 0.500 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 507 | 0.490 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2016 | 4 | 0.490 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2021 | 209 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 47 | 0.480 |
Why?
|
| Pain | 1 | 2021 | 776 | 0.480 |
Why?
|
| Tertiary Care Centers | 4 | 2017 | 177 | 0.470 |
Why?
|
| Age Factors | 14 | 2024 | 3278 | 0.460 |
Why?
|
| Videoconferencing | 4 | 2013 | 66 | 0.460 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 223 | 0.450 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2015 | 16 | 0.450 |
Why?
|
| Recurrence | 9 | 2021 | 1104 | 0.450 |
Why?
|
| Femoral Vein | 2 | 2011 | 35 | 0.440 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 2760 | 0.440 |
Why?
|
| Imaging, Three-Dimensional | 6 | 2024 | 566 | 0.430 |
Why?
|
| Hemostatic Techniques | 2 | 2011 | 50 | 0.430 |
Why?
|
| Neoplasm, Residual | 6 | 2024 | 131 | 0.430 |
Why?
|
| Telefacsimile | 1 | 2014 | 2 | 0.420 |
Why?
|
| Disease-Free Survival | 12 | 2020 | 713 | 0.420 |
Why?
|
| Endocarditis | 1 | 2014 | 38 | 0.410 |
Why?
|
| Electrocardiography | 3 | 2014 | 617 | 0.410 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 3336 | 0.410 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 396 | 0.410 |
Why?
|
| Aortic Stenosis, Supravalvular | 1 | 2013 | 4 | 0.410 |
Why?
|
| Case-Control Studies | 16 | 2024 | 3578 | 0.410 |
Why?
|
| Embolism, Air | 1 | 2013 | 14 | 0.400 |
Why?
|
| Williams Syndrome | 1 | 2013 | 13 | 0.400 |
Why?
|
| Loeys-Dietz Syndrome | 1 | 2013 | 6 | 0.400 |
Why?
|
| Coronary Stenosis | 1 | 2013 | 38 | 0.400 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2014 | 122 | 0.390 |
Why?
|
| Prospective Studies | 19 | 2024 | 7749 | 0.390 |
Why?
|
| Aneurysm | 1 | 2013 | 36 | 0.390 |
Why?
|
| Infant, Low Birth Weight | 1 | 2013 | 145 | 0.380 |
Why?
|
| Stroke Volume | 6 | 2022 | 590 | 0.370 |
Why?
|
| Hemorrhage | 3 | 2011 | 760 | 0.370 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2023 | 652 | 0.370 |
Why?
|
| Bone Diseases | 2 | 2012 | 66 | 0.370 |
Why?
|
| Antibodies, Bispecific | 2 | 2025 | 59 | 0.370 |
Why?
|
| Hypertension, Renovascular | 1 | 2011 | 15 | 0.370 |
Why?
|
| Absorbable Implants | 2 | 2020 | 35 | 0.370 |
Why?
|
| Kynurenine | 2 | 2024 | 115 | 0.360 |
Why?
|
| Renal Artery Obstruction | 1 | 2011 | 28 | 0.360 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 48 | 0.360 |
Why?
|
| Renal Artery | 1 | 2011 | 40 | 0.360 |
Why?
|
| Immunoglobulins | 4 | 2021 | 167 | 0.360 |
Why?
|
| Fractures, Spontaneous | 1 | 2011 | 16 | 0.360 |
Why?
|
| Boronic Acids | 2 | 2011 | 35 | 0.360 |
Why?
|
| Tryptophan | 2 | 2024 | 179 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 907 | 0.350 |
Why?
|
| Hospitals, Pediatric | 2 | 2018 | 532 | 0.350 |
Why?
|
| Precancerous Conditions | 3 | 2025 | 161 | 0.350 |
Why?
|
| Neoplasm Staging | 8 | 2025 | 1396 | 0.350 |
Why?
|
| Suture Techniques | 1 | 2011 | 128 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2020 | 3724 | 0.340 |
Why?
|
| Pyrazines | 2 | 2011 | 88 | 0.330 |
Why?
|
| Membrane Proteins | 1 | 2017 | 1156 | 0.330 |
Why?
|
| Transcriptome | 5 | 2020 | 1007 | 0.330 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 99 | 0.330 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 229 | 0.330 |
Why?
|
| Disease Progression | 14 | 2025 | 2791 | 0.330 |
Why?
|
| Maintenance Chemotherapy | 5 | 2025 | 38 | 0.320 |
Why?
|
| Epigenomics | 3 | 2021 | 112 | 0.320 |
Why?
|
| Platinum | 2 | 2022 | 51 | 0.320 |
Why?
|
| Surgical Instruments | 1 | 2010 | 50 | 0.320 |
Why?
|
| Airway Obstruction | 2 | 2023 | 164 | 0.320 |
Why?
|
| Arterial Pressure | 3 | 2021 | 131 | 0.310 |
Why?
|
| Weight Gain | 1 | 2013 | 537 | 0.310 |
Why?
|
| Hand Deformities, Congenital | 1 | 2009 | 10 | 0.310 |
Why?
|
| Flow Cytometry | 3 | 2015 | 1195 | 0.310 |
Why?
|
| Balloon Valvuloplasty | 3 | 2024 | 5 | 0.310 |
Why?
|
| Cytidine Deaminase | 3 | 2019 | 61 | 0.300 |
Why?
|
| Recovery of Function | 3 | 2024 | 680 | 0.300 |
Why?
|
| Coronary Circulation | 3 | 2022 | 136 | 0.300 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 1240 | 0.300 |
Why?
|
| Paraproteins | 2 | 2022 | 3 | 0.290 |
Why?
|
| Spinal Cord Diseases | 1 | 2009 | 44 | 0.290 |
Why?
|
| Ontario | 4 | 2013 | 95 | 0.290 |
Why?
|
| Catheters | 2 | 2023 | 74 | 0.290 |
Why?
|
| Climate Change | 2 | 2022 | 187 | 0.280 |
Why?
|
| Body Weight | 3 | 2025 | 992 | 0.280 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 139 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 1536 | 0.280 |
Why?
|
| DNA Copy Number Variations | 4 | 2022 | 176 | 0.280 |
Why?
|
| Repressor Proteins | 3 | 2016 | 428 | 0.280 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 247 | 0.280 |
Why?
|
| Genotype | 6 | 2019 | 1862 | 0.280 |
Why?
|
| B-Cell Maturation Antigen | 2 | 2025 | 13 | 0.280 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2021 | 188 | 0.280 |
Why?
|
| Genomic Instability | 2 | 2018 | 57 | 0.280 |
Why?
|
| Clinical Trials as Topic | 4 | 2024 | 1031 | 0.270 |
Why?
|
| Nitric Oxide | 2 | 2024 | 897 | 0.270 |
Why?
|
| Anticoagulants | 2 | 2025 | 674 | 0.270 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2019 | 39 | 0.260 |
Why?
|
| Off-Label Use | 2 | 2017 | 50 | 0.260 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2018 | 75 | 0.260 |
Why?
|
| Systole | 3 | 2022 | 175 | 0.260 |
Why?
|
| Cardiac Catheters | 2 | 2019 | 15 | 0.260 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 104 | 0.260 |
Why?
|
| Heart Failure | 5 | 2021 | 2093 | 0.260 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2019 | 308 | 0.250 |
Why?
|
| Myeloma Proteins | 3 | 2020 | 17 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2025 | 74 | 0.250 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 159 | 0.250 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 375 | 0.240 |
Why?
|
| Reference Values | 2 | 2024 | 803 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2023 | 643 | 0.240 |
Why?
|
| Mental Health | 2 | 2022 | 753 | 0.240 |
Why?
|
| Colorado | 3 | 2025 | 4597 | 0.240 |
Why?
|
| Ventricular Pressure | 1 | 2025 | 48 | 0.230 |
Why?
|
| Interferon Regulatory Factors | 2 | 2016 | 45 | 0.230 |
Why?
|
| Multicenter Studies as Topic | 2 | 2025 | 362 | 0.230 |
Why?
|
| Exome | 2 | 2017 | 238 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2016 | 163 | 0.230 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 677 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2023 | 123 | 0.230 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2025 | 337 | 0.230 |
Why?
|
| Oligopeptides | 3 | 2021 | 275 | 0.230 |
Why?
|
| Models, Statistical | 2 | 2020 | 667 | 0.230 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 69 | 0.230 |
Why?
|
| Antithrombins | 1 | 2025 | 64 | 0.230 |
Why?
|
| Risk | 4 | 2022 | 903 | 0.220 |
Why?
|
| Epigenesis, Genetic | 3 | 2020 | 655 | 0.220 |
Why?
|
| Tomography | 1 | 2025 | 45 | 0.220 |
Why?
|
| Syndecan-1 | 2 | 2021 | 41 | 0.220 |
Why?
|
| Gene Rearrangement | 2 | 2022 | 148 | 0.220 |
Why?
|
| Pulmonary Ventilation | 1 | 2025 | 83 | 0.220 |
Why?
|
| Scimitar Syndrome | 1 | 2024 | 9 | 0.220 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2018 | 526 | 0.210 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2016 | 134 | 0.210 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 1261 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2014 | 21 | 0.210 |
Why?
|
| North America | 3 | 2022 | 305 | 0.210 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2024 | 14 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2014 | 60 | 0.210 |
Why?
|
| Constriction, Pathologic | 2 | 2022 | 240 | 0.210 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2023 | 8 | 0.210 |
Why?
|
| Citrulline | 1 | 2024 | 44 | 0.210 |
Why?
|
| DNA Methylation | 2 | 2021 | 640 | 0.210 |
Why?
|
| Induction Chemotherapy | 2 | 2015 | 80 | 0.210 |
Why?
|
| Tracheobronchomalacia | 1 | 2023 | 15 | 0.210 |
Why?
|
| Vascular Closure Devices | 1 | 2023 | 6 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2014 | 17 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 1856 | 0.200 |
Why?
|
| Airway Extubation | 1 | 2024 | 60 | 0.200 |
Why?
|
| Electrocoagulation | 1 | 2023 | 35 | 0.200 |
Why?
|
| United States | 8 | 2024 | 15195 | 0.200 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 624 | 0.200 |
Why?
|
| Tomography, Optical Coherence | 2 | 2023 | 257 | 0.200 |
Why?
|
| Double-Blind Method | 5 | 2025 | 1978 | 0.200 |
Why?
|
| Ventricular Remodeling | 2 | 2022 | 258 | 0.190 |
Why?
|
| Pericardium | 1 | 2023 | 58 | 0.190 |
Why?
|
| Immunoglobulin D | 1 | 2022 | 30 | 0.190 |
Why?
|
| Arginine | 1 | 2024 | 257 | 0.190 |
Why?
|
| Societies, Medical | 2 | 2019 | 852 | 0.190 |
Why?
|
| Thrombectomy | 1 | 2023 | 75 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 193 | 0.190 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2002 | 16 | 0.190 |
Why?
|
| Thymidylate Synthase | 1 | 2002 | 12 | 0.190 |
Why?
|
| Radiation Dosage | 1 | 2024 | 189 | 0.190 |
Why?
|
| Feasibility Studies | 3 | 2025 | 1022 | 0.190 |
Why?
|
| Incidence | 5 | 2020 | 2782 | 0.190 |
Why?
|
| Registries | 5 | 2024 | 2143 | 0.190 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 433 | 0.190 |
Why?
|
| Double Outlet Right Ventricle | 1 | 2022 | 8 | 0.190 |
Why?
|
| Models, Genetic | 3 | 2020 | 587 | 0.180 |
Why?
|
| Heart Bypass, Right | 1 | 2022 | 17 | 0.180 |
Why?
|
| Drainage | 1 | 2023 | 175 | 0.180 |
Why?
|
| Thrombolytic Therapy | 2 | 2025 | 155 | 0.180 |
Why?
|
| Perfusion Imaging | 2 | 2019 | 62 | 0.180 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2020 | 217 | 0.180 |
Why?
|
| NF-kappa B | 2 | 2017 | 690 | 0.180 |
Why?
|
| Ultrasonography, Interventional | 3 | 2018 | 155 | 0.180 |
Why?
|
| Amyloidogenic Proteins | 1 | 2021 | 16 | 0.180 |
Why?
|
| Patient Discharge | 1 | 2008 | 930 | 0.180 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2022 | 145 | 0.180 |
Why?
|
| Regional Blood Flow | 2 | 2021 | 498 | 0.180 |
Why?
|
| Clone Cells | 2 | 2021 | 267 | 0.180 |
Why?
|
| Blood Volume | 2 | 2021 | 65 | 0.180 |
Why?
|
| Peptide Fragments | 1 | 2025 | 698 | 0.180 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 19 | 0.180 |
Why?
|
| Datasets as Topic | 2 | 2020 | 123 | 0.180 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 156 | 0.170 |
Why?
|
| Ventricular Function | 1 | 2021 | 57 | 0.170 |
Why?
|
| Transcriptional Elongation Factors | 2 | 2020 | 38 | 0.170 |
Why?
|
| Postoperative Period | 2 | 2022 | 360 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 207 | 0.170 |
Why?
|
| Contrast Media | 1 | 2024 | 470 | 0.170 |
Why?
|
| Performance-Enhancing Substances | 1 | 2020 | 10 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2020 | 55 | 0.170 |
Why?
|
| Pulse Wave Analysis | 2 | 2018 | 237 | 0.170 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2020 | 5 | 0.170 |
Why?
|
| Matrix Metalloproteinases | 1 | 2021 | 95 | 0.170 |
Why?
|
| Reoperation | 3 | 2018 | 590 | 0.170 |
Why?
|
| Cytoskeletal Proteins | 1 | 2021 | 156 | 0.160 |
Why?
|
| Endothelin-1 | 1 | 2022 | 177 | 0.160 |
Why?
|
| Bronchoscopy | 2 | 2023 | 225 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2017 | 15 | 0.160 |
Why?
|
| London | 2 | 2018 | 47 | 0.160 |
Why?
|
| Bronchial Diseases | 1 | 2020 | 37 | 0.160 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 118 | 0.160 |
Why?
|
| Compassionate Use Trials | 1 | 2020 | 7 | 0.160 |
Why?
|
| Signal Transduction | 4 | 2019 | 5148 | 0.160 |
Why?
|
| Arkansas | 1 | 2020 | 20 | 0.160 |
Why?
|
| Protein Folding | 1 | 2021 | 277 | 0.160 |
Why?
|
| Models, Biological | 2 | 2020 | 1822 | 0.160 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 416 | 0.160 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 208 | 0.160 |
Why?
|
| Thrombophilia | 1 | 2020 | 90 | 0.160 |
Why?
|
| Heart Function Tests | 1 | 2019 | 56 | 0.160 |
Why?
|
| Device Removal | 3 | 2017 | 140 | 0.160 |
Why?
|
| Point Mutation | 1 | 2020 | 237 | 0.160 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 21 | 0.160 |
Why?
|
| Immunomodulation | 1 | 2020 | 101 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 832 | 0.150 |
Why?
|
| Recombinant Proteins | 2 | 2025 | 1361 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2025 | 746 | 0.150 |
Why?
|
| Stress, Mechanical | 5 | 2019 | 488 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 377 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2497 | 0.150 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2020 | 122 | 0.150 |
Why?
|
| Cyanosis | 2 | 2016 | 17 | 0.150 |
Why?
|
| Aortic Valve | 2 | 2019 | 359 | 0.150 |
Why?
|
| Thoracic Injuries | 1 | 2019 | 67 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 771 | 0.150 |
Why?
|
| Vascular Access Devices | 1 | 2019 | 29 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 289 | 0.150 |
Why?
|
| Vascular System Injuries | 1 | 2019 | 76 | 0.150 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 197 | 0.150 |
Why?
|
| Pain Measurement | 1 | 2021 | 552 | 0.150 |
Why?
|
| Anxiety | 2 | 2021 | 1076 | 0.150 |
Why?
|
| Quantitative Trait Loci | 5 | 2019 | 364 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2017 | 175 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 1328 | 0.150 |
Why?
|
| Marfan Syndrome | 1 | 2018 | 43 | 0.140 |
Why?
|
| Blood Proteins | 1 | 2020 | 250 | 0.140 |
Why?
|
| Compressive Strength | 1 | 2018 | 77 | 0.140 |
Why?
|
| Risk Assessment | 8 | 2025 | 3484 | 0.140 |
Why?
|
| Protein Conformation | 1 | 2021 | 939 | 0.140 |
Why?
|
| Obesity | 2 | 2024 | 3000 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2002 | 407 | 0.140 |
Why?
|
| Length of Stay | 2 | 2024 | 1259 | 0.140 |
Why?
|
| Codon | 2 | 2017 | 92 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 51 | 0.140 |
Why?
|
| Phenotype | 5 | 2022 | 3172 | 0.140 |
Why?
|
| China | 1 | 2019 | 220 | 0.140 |
Why?
|
| Atrial Septum | 1 | 2018 | 3 | 0.140 |
Why?
|
| Europe | 4 | 2024 | 406 | 0.140 |
Why?
|
| Heart Septal Defects | 1 | 2017 | 9 | 0.140 |
Why?
|
| Renal Insufficiency | 2 | 2018 | 169 | 0.140 |
Why?
|
| Biomarkers | 6 | 2024 | 4175 | 0.140 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2018 | 78 | 0.140 |
Why?
|
| Radiation Protection | 1 | 2018 | 39 | 0.140 |
Why?
|
| Alleles | 5 | 2021 | 883 | 0.140 |
Why?
|
| Thermodilution | 1 | 2017 | 14 | 0.140 |
Why?
|
| Noonan Syndrome | 1 | 2018 | 14 | 0.140 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2017 | 30 | 0.140 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 403 | 0.140 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 157 | 0.140 |
Why?
|
| Hepatitis C | 1 | 2020 | 250 | 0.140 |
Why?
|
| Turner Syndrome | 1 | 2018 | 65 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 29 | 0.140 |
Why?
|
| Malnutrition | 1 | 2019 | 84 | 0.140 |
Why?
|
| Models, Theoretical | 2 | 2018 | 580 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 331 | 0.130 |
Why?
|
| Pressure | 3 | 2016 | 228 | 0.130 |
Why?
|
| Pain Management | 1 | 2021 | 395 | 0.130 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2017 | 5 | 0.130 |
Why?
|
| Radiography | 4 | 2016 | 844 | 0.130 |
Why?
|
| Blood Flow Velocity | 4 | 2020 | 412 | 0.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2017 | 14 | 0.130 |
Why?
|
| Dilatation | 1 | 2017 | 69 | 0.130 |
Why?
|
| Ireland | 4 | 2019 | 30 | 0.130 |
Why?
|
| Cardiologists | 1 | 2017 | 45 | 0.130 |
Why?
|
| Mental Health Services | 1 | 2022 | 445 | 0.130 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 352 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 388 | 0.130 |
Why?
|
| Pulmonary Atelectasis | 1 | 2016 | 16 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2021 | 433 | 0.130 |
Why?
|
| Genetic Pleiotropy | 1 | 2017 | 31 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 2898 | 0.130 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 505 | 0.130 |
Why?
|
| Swine | 1 | 2019 | 809 | 0.130 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 523 | 0.130 |
Why?
|
| Immunoglobulin A | 2 | 2017 | 214 | 0.130 |
Why?
|
| Vascular Remodeling | 1 | 2018 | 196 | 0.130 |
Why?
|
| Multivariate Analysis | 5 | 2021 | 1496 | 0.120 |
Why?
|
| Femoral Artery | 2 | 2023 | 184 | 0.120 |
Why?
|
| Bacteremia | 1 | 2019 | 216 | 0.120 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 179 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2024 | 5789 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2019 | 411 | 0.120 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2016 | 12 | 0.120 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 60 | 0.120 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2019 | 307 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 766 | 0.120 |
Why?
|
| Single-Cell Analysis | 2 | 2020 | 337 | 0.120 |
Why?
|
| Gene Frequency | 1 | 2017 | 492 | 0.120 |
Why?
|
| B-Lymphocytes | 2 | 2024 | 857 | 0.120 |
Why?
|
| Mitosis | 1 | 2017 | 197 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 248 | 0.120 |
Why?
|
| Genetic Variation | 3 | 2015 | 994 | 0.120 |
Why?
|
| Syndrome | 2 | 2019 | 377 | 0.120 |
Why?
|
| Immune Tolerance | 1 | 2018 | 374 | 0.120 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2015 | 3 | 0.120 |
Why?
|
| Observer Variation | 1 | 2017 | 355 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 245 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2024 | 2374 | 0.120 |
Why?
|
| Sex Characteristics | 1 | 2021 | 785 | 0.120 |
Why?
|
| MafB Transcription Factor | 1 | 2015 | 3 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2015 | 3 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 757 | 0.120 |
Why?
|
| Histones | 2 | 2021 | 638 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 2 | 2007 | 293 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2014 | 16 | 0.110 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2015 | 47 | 0.110 |
Why?
|
| Punctures | 2 | 2011 | 39 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2014 | 32 | 0.110 |
Why?
|
| Cytogenetic Analysis | 1 | 2014 | 34 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2020 | 282 | 0.110 |
Why?
|
| Fluorocarbons | 1 | 2016 | 131 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 157 | 0.110 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2014 | 8 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2014 | 35 | 0.110 |
Why?
|
| Tricuspid Atresia | 1 | 2014 | 4 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2021 | 714 | 0.110 |
Why?
|
| Truncus Arteriosus, Persistent | 1 | 2014 | 8 | 0.110 |
Why?
|
| Lung | 2 | 2025 | 4127 | 0.110 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2015 | 124 | 0.110 |
Why?
|
| Publications | 1 | 2015 | 48 | 0.110 |
Why?
|
| Bibliometrics | 1 | 2015 | 59 | 0.110 |
Why?
|
| Research Design | 2 | 2011 | 1104 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 1968 | 0.110 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 714 | 0.110 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2016 | 141 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2010 | 1054 | 0.110 |
Why?
|
| Skin Tests | 1 | 2014 | 97 | 0.110 |
Why?
|
| Kidney | 2 | 2020 | 1475 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 817 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2018 | 802 | 0.100 |
Why?
|
| Computer Communication Networks | 1 | 2013 | 32 | 0.100 |
Why?
|
| Foramen Ovale, Patent | 1 | 2013 | 10 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 897 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2016 | 244 | 0.100 |
Why?
|
| Chromosomes, Human | 1 | 2013 | 44 | 0.100 |
Why?
|
| Diseases in Twins | 1 | 2014 | 159 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 716 | 0.100 |
Why?
|
| Genetic Loci | 3 | 2020 | 276 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 116 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 2014 | 193 | 0.100 |
Why?
|
| Remote Consultation | 1 | 2013 | 59 | 0.100 |
Why?
|
| Canada | 1 | 2014 | 419 | 0.100 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2024 | 51 | 0.090 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2013 | 68 | 0.090 |
Why?
|
| Home Care Services | 2 | 2013 | 260 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2013 | 307 | 0.090 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 2152 | 0.090 |
Why?
|
| Health Surveys | 1 | 2014 | 511 | 0.090 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2012 | 198 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2011 | 46 | 0.090 |
Why?
|
| Ultrasonography | 3 | 2010 | 760 | 0.090 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2011 | 33 | 0.090 |
Why?
|
| Mothers | 1 | 2018 | 777 | 0.090 |
Why?
|
| Research | 1 | 2015 | 431 | 0.090 |
Why?
|
| Cystitis | 1 | 2011 | 23 | 0.090 |
Why?
|
| Starch | 1 | 2011 | 22 | 0.090 |
Why?
|
| Vincristine | 2 | 2020 | 131 | 0.090 |
Why?
|
| Bandages | 1 | 2011 | 42 | 0.090 |
Why?
|
| Vital Signs | 2 | 2021 | 47 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 2 | 2002 | 131 | 0.080 |
Why?
|
| Mutation Rate | 2 | 2021 | 29 | 0.080 |
Why?
|
| Hypoxia | 3 | 2024 | 1164 | 0.080 |
Why?
|
| Hemostatics | 1 | 2011 | 58 | 0.080 |
Why?
|
| Proof of Concept Study | 2 | 2021 | 85 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 256 | 0.080 |
Why?
|
| Serotonin | 2 | 2024 | 310 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 632 | 0.080 |
Why?
|
| DNA | 1 | 2017 | 1438 | 0.080 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2011 | 132 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 191 | 0.080 |
Why?
|
| Teleradiology | 1 | 2009 | 5 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2018 | 1125 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2021 | 1241 | 0.080 |
Why?
|
| Exercise Test | 1 | 2013 | 623 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1598 | 0.080 |
Why?
|
| Autografts | 2 | 2020 | 50 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2020 | 49 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2002 | 189 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2020 | 358 | 0.080 |
Why?
|
| Patient-Specific Modeling | 2 | 2020 | 42 | 0.080 |
Why?
|
| Sex Factors | 3 | 2024 | 2051 | 0.080 |
Why?
|
| Balloon Occlusion | 1 | 2009 | 36 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 805 | 0.070 |
Why?
|
| Electrodes, Implanted | 1 | 2009 | 112 | 0.070 |
Why?
|
| Aortic Aneurysm | 1 | 2009 | 70 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2015 | 691 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4407 | 0.070 |
Why?
|
| Catheterization | 1 | 2009 | 182 | 0.070 |
Why?
|
| Telemedicine | 2 | 2008 | 886 | 0.070 |
Why?
|
| Myocardial Contraction | 2 | 2020 | 303 | 0.070 |
Why?
|
| Health Care Costs | 2 | 2009 | 418 | 0.070 |
Why?
|
| Pacemaker, Artificial | 1 | 2009 | 117 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2011 | 313 | 0.070 |
Why?
|
| Histocompatibility | 1 | 2007 | 21 | 0.070 |
Why?
|
| Pregnancy | 3 | 2018 | 7035 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2007 | 79 | 0.070 |
Why?
|
| Apoptosis | 1 | 2016 | 2571 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 1093 | 0.070 |
Why?
|
| Critical Care | 1 | 2013 | 650 | 0.070 |
Why?
|
| Telephone | 1 | 2008 | 180 | 0.070 |
Why?
|
| Elastic Modulus | 2 | 2019 | 123 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2008 | 690 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 66 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2020 | 1441 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2012 | 707 | 0.070 |
Why?
|
| Global Health | 2 | 2020 | 381 | 0.060 |
Why?
|
| Materials Testing | 2 | 2019 | 353 | 0.060 |
Why?
|
| Chromatin | 2 | 2021 | 533 | 0.060 |
Why?
|
| Neonatal Screening | 1 | 2008 | 172 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 333 | 0.060 |
Why?
|
| Protein Binding | 3 | 2017 | 2238 | 0.060 |
Why?
|
| Chromosome Mapping | 2 | 2019 | 504 | 0.060 |
Why?
|
| Health Personnel | 2 | 2022 | 724 | 0.060 |
Why?
|
| Asthma | 1 | 2018 | 1919 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 274 | 0.060 |
Why?
|
| England | 3 | 2013 | 108 | 0.060 |
Why?
|
| HIV Infections | 1 | 2020 | 2967 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 2056 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 5931 | 0.060 |
Why?
|
| Logistic Models | 1 | 2010 | 2088 | 0.060 |
Why?
|
| Hirudins | 1 | 2025 | 52 | 0.060 |
Why?
|
| Proteomics | 2 | 2023 | 1136 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 284 | 0.060 |
Why?
|
| Triazines | 1 | 2025 | 45 | 0.060 |
Why?
|
| beta 2-Microglobulin | 1 | 2005 | 49 | 0.060 |
Why?
|
| Indazoles | 1 | 2025 | 74 | 0.060 |
Why?
|
| Stroke | 1 | 2013 | 1158 | 0.060 |
Why?
|
| Kynurenic Acid | 1 | 2024 | 18 | 0.060 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2024 | 4 | 0.060 |
Why?
|
| Electric Impedance | 1 | 2025 | 112 | 0.050 |
Why?
|
| Equipment Failure | 2 | 2019 | 111 | 0.050 |
Why?
|
| Trisomy | 1 | 2025 | 78 | 0.050 |
Why?
|
| Cost of Illness | 2 | 2020 | 310 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2007 | 405 | 0.050 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 277 | 0.050 |
Why?
|
| Social Support | 1 | 2008 | 629 | 0.050 |
Why?
|
| Triazoles | 1 | 2025 | 162 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 28 | 0.050 |
Why?
|
| Anthropometry | 1 | 2024 | 208 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 438 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 93 | 0.050 |
Why?
|
| Disease Management | 2 | 2020 | 628 | 0.050 |
Why?
|
| Animals | 3 | 2019 | 37579 | 0.050 |
Why?
|
| Dual Oxidases | 1 | 2023 | 4 | 0.050 |
Why?
|
| Alkanesulfonic Acids | 1 | 2023 | 48 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1046 | 0.050 |
Why?
|
| Silicates | 1 | 2023 | 18 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2004 | 141 | 0.050 |
Why?
|
| Equipment Failure Analysis | 2 | 2016 | 131 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 320 | 0.050 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2002 | 12 | 0.050 |
Why?
|
| Life Tables | 1 | 2002 | 20 | 0.050 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2022 | 9 | 0.050 |
Why?
|
| Paraproteinemias | 1 | 2022 | 5 | 0.050 |
Why?
|
| Consensus Sequence | 1 | 2002 | 74 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 589 | 0.050 |
Why?
|
| Cause of Death | 1 | 2005 | 441 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 284 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 545 | 0.050 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2002 | 18 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2002 | 64 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2002 | 13 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2023 | 157 | 0.050 |
Why?
|
| Cell Count | 1 | 2002 | 325 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 2780 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 47 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2023 | 162 | 0.040 |
Why?
|
| Germinal Center | 1 | 2002 | 66 | 0.040 |
Why?
|
| Replantation | 1 | 2021 | 31 | 0.040 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2021 | 16 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2021 | 6 | 0.040 |
Why?
|
| Telomere | 1 | 2024 | 279 | 0.040 |
Why?
|
| Chromosomes | 1 | 2021 | 105 | 0.040 |
Why?
|
| Sirolimus | 1 | 2023 | 276 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 3487 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2021 | 26 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 73 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2020 | 42 | 0.040 |
Why?
|
| Polydioxanone | 1 | 2020 | 4 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 236 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 84 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2020 | 10 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2002 | 272 | 0.040 |
Why?
|
| CpG Islands | 1 | 2021 | 163 | 0.040 |
Why?
|
| Folic Acid | 1 | 2002 | 198 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 34 | 0.040 |
Why?
|
| Photoplethysmography | 1 | 2020 | 18 | 0.040 |
Why?
|
| Prednisolone | 1 | 2020 | 68 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1490 | 0.040 |
Why?
|
| Placebos | 1 | 2020 | 195 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 143 | 0.040 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2020 | 54 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2020 | 134 | 0.040 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2019 | 6 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 76 | 0.040 |
Why?
|
| Aminohydrolases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Smoking | 2 | 2004 | 1573 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 102 | 0.040 |
Why?
|
| Cytosine Deaminase | 1 | 2019 | 16 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 58 | 0.040 |
Why?
|
| Airway Management | 1 | 2020 | 71 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 110 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2017 | 1313 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 594 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 142 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 1052 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 110 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 197 | 0.040 |
Why?
|
| Parents | 1 | 2008 | 1440 | 0.040 |
Why?
|
| Collateral Circulation | 1 | 2019 | 20 | 0.040 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2020 | 147 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 699 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 415 | 0.040 |
Why?
|
| RNA Interference | 1 | 2021 | 468 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2023 | 556 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 85 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2020 | 211 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2020 | 238 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2019 | 30 | 0.040 |
Why?
|
| Transplantation | 1 | 2019 | 33 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 76 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2018 | 60 | 0.040 |
Why?
|
| Karyotyping | 2 | 2013 | 104 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 624 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 267 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 624 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 508 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2019 | 68 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2023 | 598 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 111 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2235 | 0.040 |
Why?
|
| Altitude | 1 | 2023 | 473 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 453 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2018 | 136 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1491 | 0.040 |
Why?
|
| Quality Control | 1 | 2018 | 162 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2018 | 254 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 69 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 2018 | 288 | 0.040 |
Why?
|
| Vascular Resistance | 2 | 2019 | 364 | 0.030 |
Why?
|
| Shear Strength | 1 | 2018 | 68 | 0.030 |
Why?
|
| Poland | 1 | 2018 | 35 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 393 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 311 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 956 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 158 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 119 | 0.030 |
Why?
|
| Heart Rate | 2 | 2021 | 821 | 0.030 |
Why?
|
| Food Supply | 1 | 2019 | 90 | 0.030 |
Why?
|
| Physical Chromosome Mapping | 1 | 2017 | 20 | 0.030 |
Why?
|
| Telemetry | 2 | 2008 | 40 | 0.030 |
Why?
|
| Body Size | 1 | 2018 | 95 | 0.030 |
Why?
|
| Cardiac Output | 2 | 2017 | 177 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 418 | 0.030 |
Why?
|
| Transcription Elongation, Genetic | 1 | 2017 | 23 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2004 | 833 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2018 | 243 | 0.030 |
Why?
|
| Cell Size | 1 | 2017 | 89 | 0.030 |
Why?
|
| Public Health | 1 | 2022 | 554 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2017 | 60 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 2017 | 40 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 327 | 0.030 |
Why?
|
| Instillation, Drug | 1 | 2016 | 10 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 740 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 1141 | 0.030 |
Why?
|
| Internet | 2 | 2013 | 682 | 0.030 |
Why?
|
| Cell Survival | 1 | 2020 | 1129 | 0.030 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2017 | 62 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2020 | 479 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2020 | 598 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 605 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 229 | 0.030 |
Why?
|
| Immunoassay | 1 | 2017 | 113 | 0.030 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2016 | 8 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2017 | 63 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 423 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 310 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 415 | 0.030 |
Why?
|
| Quality of Life | 2 | 2019 | 3005 | 0.030 |
Why?
|
| HLA-DRB1 Chains | 1 | 2017 | 111 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 74 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2016 | 66 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2017 | 287 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 336 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2019 | 398 | 0.030 |
Why?
|
| International Agencies | 1 | 2015 | 32 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 85 | 0.030 |
Why?
|
| Health Policy | 1 | 2019 | 380 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2016 | 124 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2015 | 11 | 0.030 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2016 | 66 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 125 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2015 | 14 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 218 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 562 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 949 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 837 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 187 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 702 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 137 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 391 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 339 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 173 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1658 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2014 | 85 | 0.030 |
Why?
|
| Mice | 1 | 2011 | 18057 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 93 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 516 | 0.030 |
Why?
|
| Oxygen | 1 | 2018 | 992 | 0.030 |
Why?
|
| Acute Disease | 2 | 2009 | 1010 | 0.020 |
Why?
|
| Alloys | 1 | 2013 | 38 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2017 | 553 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 544 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 1763 | 0.020 |
Why?
|
| Software | 1 | 2017 | 676 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 332 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2017 | 664 | 0.020 |
Why?
|
| Binding Sites | 1 | 2014 | 1315 | 0.020 |
Why?
|
| Hematoma | 1 | 2011 | 54 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2011 | 74 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 2920 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 4199 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2010 | 80 | 0.020 |
Why?
|
| Hospitals, District | 1 | 2009 | 6 | 0.020 |
Why?
|
| Northern Ireland | 1 | 2009 | 12 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2009 | 23 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 521 | 0.020 |
Why?
|
| Cardiology Service, Hospital | 1 | 2009 | 28 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 53 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2604 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2017 | 1196 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 651 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 361 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2822 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2009 | 181 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 712 | 0.020 |
Why?
|
| Siblings | 1 | 2007 | 216 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 5645 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 772 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2010 | 923 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 684 | 0.010 |
Why?
|
| Asia | 1 | 2005 | 68 | 0.010 |
Why?
|
| Platelet Count | 1 | 2005 | 89 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2004 | 6 | 0.010 |
Why?
|
| International Cooperation | 1 | 2005 | 195 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2005 | 152 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2004 | 117 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 308 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 1815 | 0.010 |
Why?
|
| Aging | 1 | 2014 | 1917 | 0.010 |
Why?
|
| Creatinine | 1 | 2005 | 490 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2002 | 10 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 25 | 0.010 |
Why?
|
| DNA Repair | 1 | 2004 | 239 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 397 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 381 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 1015 | 0.010 |
Why?
|
| Phenytoin | 1 | 1970 | 21 | 0.010 |
Why?
|
| Digoxin | 1 | 1970 | 26 | 0.010 |
Why?
|
| Ventricular Fibrillation | 1 | 1970 | 62 | 0.000 |
Why?
|
| Dogs | 1 | 1970 | 426 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1970 | 384 | 0.000 |
Why?
|